EnnoDC develops a protein-based vaccine platform that utilizes humanized monoclonal antibodies fused with pathogen regions to target the CD40 molecule on dendritic cells. This technology enables the creation of vaccines for diseases such as HIV, SARS-CoV-2 variants, and HPV-related cancers, addressing the need for effective immunization against multiple pathogens.
Funding
$7.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccine development faces challenges in achieving effective immune responses, particularly for complex pathogens like HIV and rapidly mutating viruses such as SARS-CoV-2. Traditional vaccine approaches may not efficiently activate dendritic cells, which are crucial for initiating robust and long-lasting immunity. Furthermore, developing effective vaccines for HPV-related cancers remains a significant unmet need.
Solution
EnnoDC is developing a protein-based vaccine platform that leverages humanized monoclonal antibodies fused with pathogen-specific antigens to target the CD40 molecule on dendritic cells. By specifically engaging CD40, the platform aims to enhance dendritic cell activation, leading to a more potent and targeted immune response. This approach is being applied to develop vaccines against infectious diseases, including HIV and SARS-CoV-2 variants, as well as HPV-induced cancers. The platform's modular design allows for rapid adaptation to new viral strains and cancer targets.
Target Audience
The primary target audience includes individuals at risk of infection from HIV, SARS-CoV-2 variants, and HPV, as well as patients diagnosed with HPV-related cancers and prostate cancer.
Features
- Humanized monoclonal antibodies that specifically bind to the CD40 receptor on dendritic cells.
- Fusion of antibody with pathogen-derived antigens to deliver targeted stimulation.
- Modular platform enabling rapid adaptation to emerging viral variants and cancer targets.
- Potential for enhanced T cell and B cell responses compared to traditional vaccines.
- Clinical and preclinical development programs in HPV-induced cancers, prostate cancer, and infectious diseases.